Citius Oncology (CTOR), a majority-owned subsidiary of Citius Pharmaceuticals (CTXR), announced that it has retained Jefferies (JEF) as its exclusive financial advisor to assist in evaluating strategic alternatives aimed at maximizing shareholder value. The engagement of Jefferies underscores Citius Oncology’s commitment to exploring all avenues for enhancing its strategic positioning and advancing its mission to improve patient outcomes in oncology. Strategic alternatives under consideration may include, but are not limited to, partnerships, joint ventures, mergers, acquisitions, licensing or other strategic transactions.
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CTOR:
- American Air upgraded, Nordstrom downgraded: Wall Street’s top analyst calls
- Citius Pharmaceuticals upgraded to Buy from Hold at D. Boral Capital
- Citius Oncology initiated with a Buy at Maxim
- Biotech Alert: Searches spiking for these stocks today
- Citius Pharmaceuticals, Citius Oncology report promising cancer trial results